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End-Stage Liver Disease Candidates at the Highest
Model for End-Stage Liver Disease Scores Have Higher
Wait-List Mortality Than Status-1A Candidates
Pratima Sharma,1 Douglas E. Schaubel,2 Qi Gong,2 Mary Guidinger,4 and Robert M. Merion3,4
Candidates with fulminant hepatic failure (Status-1A) receive the highest priority for liver
transplantation (LT) in the United States. However, no studies have compared wait-list
mortality risk among end-stage liver disease (ESLD) candidates with high Model for End-
Stage Liver Disease (MELD) scores to those listed as Status-1A. We aimed to determine if
there are MELD scores for ESLD candidates at which their wait-list mortality risk is
higher than that of Status-1A, and to identify the factors predicting wait-list mortality
among those who are Status-1A. Data were obtained from the Scientiﬁc Registry of Trans-
plant Recipients for adult LT candidates (n 5 52,459) listed between September 1, 2001,
and December 31, 2007. Candidates listed for repeat LTas Status-1 A were excluded. Start-
ing from the date of wait listing, candidates were followed for 14 days or until the earliest
occurrence of death, transplant, or granting of an exception MELD score. ESLD candi-
dates were categorized by MELD score, with a separate category for those with calculated
MELD > 40. We compared wait-list mortality between each MELD category and Status-
1A (reference) using time-dependent Cox regression. ESLD candidates with MELD > 40
had almost twice the wait-list mortality risk of Status-1A candidates, with a covariate-
adjusted hazard ratio of HR 5 1.96 (P 5 0.004). There was no difference in wait-list mor-
tality risk for candidates with MELD 36-40 and Status-1A, whereas candidates with
MELD < 36 had signiﬁcantly lower mortality risk than Status-1A candidates. MELD score
did not signiﬁcantly predict wait-list mortality among Status-1A candidates (P 5 0.18).
Among Status-1A candidates with acetaminophen toxicity, MELD was a signiﬁcant predic-
tor of wait-list mortality (P < 0.0009). Posttransplant survival was similar for Status-1A
and ESLD candidates with MELD > 20 (P 5 0.6). Conclusion: Candidates with MELD >
40 have signiﬁcantly higher wait-list mortality and similar posttransplant survival as
candidates who are Status-1A, and therefore, should be assigned higher priority than
Status-1A for allocation. Because ESLD candidates with MELD 36-40 and Status-1A
have similar wait-list mortality risk and posttransplant survival, these candidates
should be assigned similar rather than sequential priority for deceased donor LT.
(HEPATOLOGY 2012;55:192-198)
L
iver transplantation (LT) is the only therapeutic
option for candidates with fulminant hepatic
failure (FHF) and those with decompensated
end-stage liver disease (ESLD). Candidates with FHF
are listed as Status-1A on the transplant waiting list
and receive the highest priority for deceased donor
LT.1 These candidates are ordered by their waiting
time on the wait-list.
The Organ Procurement and Transplantation Net-
work (OPTN) deﬁnes FHF as the onset of hepatic
encephalopathy within 8 weeks of the ﬁrst symptoms
of liver disease in the absence of pre-existing liver dis-
ease, in the intensive care unit, meeting at least one of
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three criteria: (1) ventilator dependence, (2) requiring
renal replacement therapy, or (3) international normal-
ized ratio (INR) of prothrombin time >2.0 with a life
expectancy of 7 days or less without LT.1 FHF is asso-
ciated with high mortality in the absence of transplant,
with variation in prognosis based on patient age, etiol-
ogy, and grade of hepatic encephalopathy.
ESLD candidates are prioritized after Status-1A
based on their Model for End-Stage Liver Disease
(MELD) score.1 MELD score is a predictor of wait-list
mortality and is calculated using the candidate’s serum
bilirubin, creatinine and INR2 and was adopted as the
basis for deceased donor liver allocation by the OPTN
in February 2002.3,4 The national allocation policy for
donor livers is based on nested rules pertaining to wait-
list mortality and geography. The Status-1 category was
further subdivided into Status-1A and Status-1B. This
policy went into effect on August 24, 2005.1 Donor
livers are ﬁrst offered to Status-1A candidates with
FHF or immediate post-LT graft failure, followed by
Status-1B (pediatric candidates with chronic liver dis-
ease in an intensive care unit). Candidates with ESLD
are allocated organs after Status-1A candidates in de-
scending order of MELD or Pediatric End-Stage Liver
Disease (PELD) score.1 For allocation purposes, these
scores are capped by the OPTN at 40. However, data
from previous studies showed that candidates with
MELD scores >40 have higher wait-list mortality than
candidates with a MELD score of 40.3,5
ESLD candidates with higher MELD scores have
higher wait-list mortality risk compared to those with
lower MELD scores.3 However, there are no studies
comparing the wait-list mortality risk of FHF candi-
dates listed as Status-1A to the wait-list mortality risk
of ESLD candidates with high MELD scores. More-
over, it has been tacitly assumed that wait-list mortality
risk among FHF Status-1A candidates is equal, regard-
less of MELD score. In fact, one previous study sug-
gested further stratiﬁcation of Status-1A by diagnosis
to address this issue.5
The primary objective of the current study was to
determine if there are MELD scores at which the wait-list
mortality risk of ESLD candidates is higher than that of
FHF Status-1A candidates and to identify predictors of
wait-list mortality risk among Status-1A candidates.
Patients and Methods
Data Source and Study Population. This study
used data from the Scientiﬁc Registry of Transplant
Recipients (SRTR) submitted by the members of the
OPTN. Mortality information was supplemented by
data from the Social Security Death Master File.
In order to avoid cohort heterogeneity due to subdi-
vision of Status-1 into Status-1A and Status-1B in Au-
gust 2005, our study population included all adult
candidates (age 18 years) listed as Status-1 (before
the policy change) and Status-1A (after the policy
change) for FHF, with an initial date of registration
for deceased donor LT between September 1, 2001,
and December 31, 2007, a priori, and refer to all such
candidates hereafter as Status-1A in this article. The
start date of the study corresponded to the initial date
of mandatory submission of the three components of
the MELD score. Because this policy change for Sta-
tus-1 mainly affected pediatric candidates, our study
excluded candidates <18 years of age listed as Status-1
or Status-1B as well as candidates listed for repeat LT
as Status-1 or Status-1A for primary nonfunction.
The primary outcome was wait-list mortality within
2 weeks of listing. Candidates were followed from the
time of listing until death, receipt of LT, the granting
of exception MELD score, or 14 days after listing,
whichever occurred the earliest. The majority of Sta-
tus-1A candidates with FHF receive a transplant,
recover, or die within 14 days of listing. Moreover, a
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request to continue a Status-1A listing beyond 14 days
results in a review of all local Status-1A liver candidate
listings.1 For these reasons and in the light of our
objectives, an a priori follow-up period of 2 weeks af-
ter listing was considered to be the most relevant.
FHF candidates listed as Status-1A were stratiﬁed as
related to acetaminophen toxicity and nonacetamino-
phen etiology, based on diagnosis codes. To avoid mis-
classiﬁcation, the etiology of FHF was ascertained
manually. The etiology of FHF Status-1A candidates
was coded as acetaminophen if the primary or second-
ary diagnosis data ﬁeld indicated any mention of acet-
aminophen, (Tylenol [McNeil-PPC, Fort Washington,
PA]) or drugs containing acetaminophen (such as
Vicodin [Abbott Laboratories, Abbott Park, IL], Dar-
vocet [AAIPharma, Wilmington, NC], APAP-hydroco-
done, Percocet [Endo Pharmaceuticals, Chadds Ford,
PA], and so forth). All other FHF candidates listed as
Status-1A were coded as nonacetaminophen.
Statistical Analysis. For descriptive purposes, con-
tinuous variables were presented as mean 6 standard
deviation, whereas levels of categorical variables were
presented as percentages. Kaplan–Meier analysis was
used to estimate unadjusted wait-list survival probabil-
ities. For wait-list survival, candidates were followed
from listing until death, receipt of LT, or 14 days after
listing. Note that for this part of the analysis, wait-list
candidates were classiﬁed on the basis of their MELD
and/or Status at listing, due to the technical (as well as
conceptual) difﬁculties associated with estimating sur-
vival curves in the presence of time-dependent covari-
ates; e.g., as discussed in Kalbﬂeisch and Prentice6 and
Schaubel et al.7
Cox regression analysis was used to model wait-list
mortality. MELD and Status-1A were coded as time-
dependent covariates, such that changes in MELD
score and Status-1A were factored into the modeling.
Status-1A served as the reference category, to which
each MELD category was compared. Mortality con-
trasts between each MELD category and Status-1A
were quantiﬁed by the hazard ratio (HR), which (for a
particular MELD category) can be interpreted as the
covariate-adjusted ratio of death rates, with the death
rate for Status-1A (HR ¼ 1) serving as the denomina-
tor. ESLD candidates with a calculated MELD score
>40 were assigned to the ‘‘MELD > 40’’ category.
Cox models were stratiﬁed by organ procurement or-
ganization and adjusted for age, sex, race, diagnosis,
dialysis, albumin, and diabetes and hospitalization sta-
tus at listing.
Using only the Status-1A candidates, we then ﬁtted
Cox models to assess the impact of MELD score on
wait-list mortality. First, we ﬁtted a model to all Sta-
tus-1A candidates; second, we ﬁtted separate models to
the Status-1A–acetaminophen and Status-1A–nonaceta-
minophen candidates. The model was adjusted for age,
sex, race, diagnosis, dialysis, albumin, and diabetes and
hospitalization status at listing. We also evaluated the
interaction between MELD and calendar year of list-
ing, for the wait-list mortality model.
Kaplan–Meier analysis was used to estimate unad-
justed posttransplant survival probabilities. Candidates
were followed from the time of transplant until the
earliest of death, a duration of 3 years after transplant,
or the end of the follow-up period.
Finally, we ﬁtted Cox models to contrast Status-1A
(reference) and the MELD categories with respect to
posttransplant mortality. Included in this component
of the analysis were all patients from the original study
cohort who received a ﬁrst deceased donor LT during
the observation period. We adjusted for all covariates
listed previously, as well as time between wait-listing
and transplant, and donor risk index.8 Cox regression
analysis was used to compare the post-LT survival anal-
ysis among all LT recipients. All statistical analyses
were conducted using SAS version 9.2 (SAS Institute,
Cary, NC).
Results
Description of Cohort. A total of n ¼ 52,459 can-
didates (Status-1A candidates: n ¼ 2128; ESLD candi-
dates: n ¼ 50,331) aged 18 years were listed for
deceased donor LT between September 1, 2001, and
December 31, 2007. Of the Status-1A candidates, 485
(23%) were classiﬁed as acetaminophen whereas the
remaining 1643 (77%) were classiﬁed as nonacetami-
nophen. The baseline characteristics of such candidates
before and after the policy change were similar (data
not shown). Characteristics of the Status-1A and
ESLD candidates are listed in Table 1. The acetamino-
phen Status-1A candidates tended to be younger, more
likely to be white and female, and had lower body
mass index than candidates who were nonacetamino-
phen Status-1A (Table 1). Approximately 34% of acet-
aminophen Status-1A candidates were on renal replace-
ment therapy at listing, compared with 60% of
nonacetaminophen Status-1A candidates.
MELD Distribution at the Time of Listing. Figure
1 shows the distribution of MELD score at the time
of listing among Status-1A and ESLD candidates. A
total of 576 (27%) Status-1A candidates had a calcu-
lated MELD score > 40 at the time of listing, whereas
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813 (1.6%) ESLD candidates had MELD > 40 at
listing.
Wait-list Mortality Among ESLD and Status-1A
Candidates. There were a total of 333 and 1302 wait-
list deaths among Status-1A and ESLD candidates,
respectively, within 2 weeks of listing. Figure 2 shows
the candidate survival stratiﬁed by Status-1A and
ESLD candidates with MELD score 36-40 and > 40.
The 14-day wait-list survival probability was estimated
at 71% for Status-1A, 70% for MELD score 36-40
and 52% for candidates with MELD > 40.
Results from the Cox regression analysis comparing
ESLD candidates in each MELD category to Status-
1A (reference: HR ¼ 1) are shown in Fig. 3. Candi-
dates in all MELD score categories less than 36 had
signiﬁcantly lower wait-list mortality risk compared to
Status-1A. Candidates with MELD scores 36 to 40
had similar wait-list mortality risk compared to those
at Status-1A. Compared to Status-1A candidates, those
with MELD score > 40 had signiﬁcantly higher wait-
list mortality risk, with a covariate-adjusted hazard ra-
tio [HR] of HR ¼ 1.96 (P < 0.0001). Hence, candi-
dates with MELD scores >40 (which are capped at 40
by the OPTN for allocation purposes) had approxi-
mately twice the covariate-adjusted wait-list mortality
risk of Status-1A candidates. Wait-list mortality risk
among acetaminophen Status-1A candidates was not
signiﬁcantly different than that of nonacetaminophen
Status-1A candidates. Similarly, the wait-list mortality
risk for Status-1A candidates was not signiﬁcantly dif-
ferent before versus after the policy change for Status-1
in August 2005 (HR ¼ 0.82; P ¼ 0.11).
Predictors of Wait-list Mortality Among Status-1A
Candidates. In Table 2, we list results from wait-list
mortality models ﬁtted for Status-1A candidates only.
Separate Cox models were also ﬁtted to acetamino-
phen and nonacetaminophen Status-1A candidates.
MELD score was a signiﬁcant predictor of wait-list
mortality among acetaminophen Status-1A candidates,
with a covariate-adjusted hazard ratio of HR ¼ 1.071
(P ¼ 0.009) indicating that each one point increase in
MELD score was associated with a 7.1% increase in
wait-list mortality, after adjustment for age, sex, race,
diagnosis, dialysis, albumin, and diabetes and hospital-
ization status. MELD was not found to have a signiﬁ-
cant association with wait-list mortality among nonace-
taminophen Status-1A candidates, with HR ¼ 0.998
(P ¼ 0.86). Interestingly, the interaction between
MELD and listing year on wait-list mortality among
nonacetaminophen Status-1A candidates was signiﬁ-
cant (HR ¼ 0.99; P ¼ 0.046), suggesting that the
effect of MELD on wait-list mortality has been
decreasing in more recent years for these candidates.
Hospitalization in the intensive care unit (HR ¼
2.06; P ¼ 0.001) and receipt of dialysis (HR ¼ 1.97,
P < 0.0001) were the only other signiﬁcant predictors
of wait-list mortality among all Status-1A candidates.
Post-LT Survival Rates Among Status-1A and
ESLD Recipients. Figure 4 shows the unadjusted post-
transplant survival for Status-1A and MELD > 20
Table 1. Characteristics of Status-1A (Acetaminophen and
Nonacetaminophen) and ESLD Candidates at Listing
Variables
Status-1A (N ¼ 2128)
ESLD
(N ¼ 50,331)
Acetaminophen
(N ¼ 485)
Nonacetaminophen
(N ¼ 1643)
Age (years) 33 6 11.2 40.5 6 14.1 52.5 6 13.5
% Male 0.22 0.35 0.65
White 0.81 0.58 0.75
Black 0.09 0.21 0.07
Hispanic 0.07 0.12 0.14
Others 0.03 0.09 0.04
MELD Score 35 6 6.7 33 6 7.3 16 6 7.6
Dialysis 0.13 0.08 0.033
Body mass index 24.6 6 5.1 29.3 6 5.4 32.5 6 5.8
Fig. 1. MELD score distribution at listing among ESLD and Status-
1A candidates.
Fig. 2. Kaplan–Meier wait-list survival curves for patients listed at
Status-1A and MELD scores of 36-40 and > 40.
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recipients. The 1-, 2-, and 3-year posttransplant sur-
vival was 81%, 79%, and 78% for Status-1A and
84%, 79% and 76% for recipients with MELD score
> 20. In the Cox regression analysis, there were no
signiﬁcant differences in post-LT mortality risk
between Status-1A and ESLD recipients in any sub-
group of MELD > 20 (Fig. 5).
Discussion
This is the ﬁrst study to compare wait-list mortality
risk among Status-1A and ESLD candidates with high
MELD scores. Our analysis showed that ESLD candi-
dates with MELD scores 36 to 40 had similar wait-list
mortality risk as Status-1A candidates, and those with
MELD scores > 40 had signiﬁcantly higher wait-list
mortality risk than Status-1A candidates. Importantly,
post-LT survival was similar among Status-1A and all
groups of ESLD candidates with MELD scores > 20,
suggesting that futility concerns for those with the
highest MELD scores are largely unfounded, given
current practices. Our results also showed that wait-list
mortality risk is not homogeneous among Status-1A
candidates; MELD was a signiﬁcant independent pre-
dictor of wait-list mortality in the acetaminophen Sta-
tus-1A subgroup.
Although the MELD score was adopted in February
2002 as the measure of wait-list urgency used to allo-
cate donor liver allografts to ESLD candidates, the
allocation process for Status-1A candidates has
remained unchanged and still uses waiting time as the
primary allocation criterion.1,4 Previous studies evalu-
ating the wait-list mortality risk of ESLD candidates
excluded Status-1A candidates.2,3,9 For ESLD candi-
dates, Merion et al. showed that wait-list mortality risk
increased exponentially with increasing MELD score;
the unadjusted wait-list mortality rates were 4364 per
1000 patient years at MELD scores of 30-39 and
13,153 per 1000 patient years at MELD scores of 40.9
In addition, Wiesner et al. and Kamath et al., in their
MELD validation studies, estimated the 3-month
death probability to be 60%-83% and 79%-100% for
ESLD candidates with MELD scores 30-39 and 40,
respectively.2,3
Given the sequential nature of the current allocation
system, our study results, showing similar wait-list
Fig. 3. Comparing covariate-adjusted wait-
list mortality risk between ESLD and Status-
1A candidates. Status-1A is the reference
group (HR set to 1). Compared to Status-1A
candidates, ESLD candidates with MELD
score  35 have lower wait-list mortality risk;
ESLD candidates with MELD score 36-40
have similar wait-list mortality risk; and ESLD
candidates with MELD scores > 40 have
higher wait-list mortality risk.
Table 2. Effect of MELD on Wait-List Mortality Risk Among
Status-1A Candidates
Model* Hazard Ratio† (95% CI) P Value
All Status-1A 1.012 (0.995,1.029) 0.1837
Acetaminophen Status-1A 1.070 (1.028, 1.114) 0.0009
Nonacetaminophen Status-1A 0.998 (0.980, 1.017) 0.86
*Three separate models stratiﬁed by organ procurement organization.
†Adjusted for age, sex, race, diagnosis, dialysis, albumin, and diabetes and
hospitalization status.
Fig. 4. Kaplan–Meier posttransplant survival curves for recipients
who underwent transplantation at Status-1A and MELD > 20.
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mortality risk and similar early, as well as overall post-
LT mortality risk among Status-1A and high MELD
candidates, have important implications for ESLD can-
didates with high MELD scores. For instance, in
2007, the median time to LT among Status-1A candi-
dates was 5 days, compared to 15 days for candidates
with MELD 30. Candidates with high MELD scores
(36-40) wait longer than candidates at Status-1A to
receive an allograft,10,11 prolonging their exposure to
the risk of wait-list death. Thus, despite similar risk of
wait-list death per unit time, the longer exposure for
the ESLD candidates of necessity results in a lower
proportion transplanted and a higher proportion who
die on the wait-list. Because the intent of current liver
allocation policy is to reduce wait-list mortality, ESLD
candidates with MELD scores 36-40 should receive
similar priority to Status-1A for deceased donor LT.
In our study, ESLD candidates with actual MELD
scores > 40 had the highest risk of dying on the wait-
list and had similar post-LT survival as Status-1A, sug-
gesting that liver transplant survival beneﬁt among
MELD > 40 candidates was greater than that of Sta-
tus-1A patients. However, these candidates are grouped
together with those ESLD candidates whose MELD
scores are exactly 40. Given the higher wait-list mor-
tality risk among those with MELD scores > 40, the
arbitrary capping of MELD score at 40 appears to
have harmed these candidates and further increased
the overall mortality among this sickest group of can-
didates. Rank ordering by calculated MELD score
beyond 40 may improve the chances of getting an
offer in a timely manner for candidates with MELD
> 40 and may decrease their wait-list mortality.
Status-1A candidates currently beneﬁt from broader
sharing of organs. This mechanism is not available to
patients with high MELD scores. Moreover, the
impact of broader sharing upon wait-list mortality
among high MELD patients is not known. Given the
comparable mortality risk of Status-1A and MELD >
40 candidates, admixture of these candidate pools into
the current regional sharing tier of organ distribution
would also be reasonably expected to have a salutary
effect on mortality. This change in allocation policy
could be studied by simulation modeling or by a
regionally based pilot study as was conducted for
MELD  29 patients in Region 8.12
Although the MELD score is not currently consid-
ered in the allocation of liver allografts to Status-1A
candidates, several studies have suggested prognostic
value of MELD score in certain subsets of candidates
with acute liver failure.5,13-16 In one study, a higher
MELD score was predictive of the development of
FHF, but once FHF developed, the MELD score was
not any more accurate at predicting survival than ei-
ther the King’s College criteria or INR alone.16 In
another study from the pre-MELD era of 720 adult
Status-1A candidates, nonacetaminophen, FHF candi-
dates had the poorest overall survival on the liver
transplant wait-list, and higher MELD score was
highly correlated with lower survival in this group.5
Our study from the MELD era, found that every unit
increase in MELD score was associated with 7%
increase in wait-list mortality risk among acetamino-
phen FHF Status-1A candidates. This is a novel
ﬁnding.
The effect of MELD score on wait-list mortality
risk was not seen in nonacetaminophen FHF Status-
1A candidates, in distinction to the study by Kremers
et al.5 The signiﬁcant interaction between MELD and
listing year on wait-list mortality among
Fig. 5. Comparing covariate-adjusted post-
transplant mortality risk between ESLD and
Status-1A candidates. Status-1A is the refer-
ence group (HR set to 1). Compared to Sta-
tus-1A, ESLD candidates with MELD score 
20 have lower overall posttransplant mortality
risk; ESLD candidates with MELD scores of
21-40 and >40 have similar posttransplant
mortality risk.
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nonacetaminophen FHF Status-1A candidates in our
study suggests that the impact of MELD in this sub-
group signiﬁcantly diminished as calendar time pro-
gressed. Our study and that by Kremers et al.5 are
markedly different. The present study used a cohort
ﬁve times larger than that of Kremers et al. (N ¼
1643 versus N ¼ 312), analyzed outcomes since the
collection of MELD components was initiated, and
included patients with Wilson’s disease. Changes in
practice patterns, including earlier referral of fulminant
liver failure patients to liver transplant centers and
improved intensive care unit care may account for the
lack of association between MELD and wait-list mor-
tality outcome for nonacetaminophen FHF candidates.
The main limitation of our study relates to its retro-
spective observational design, which results in the
potential for bias due to unmeasured patient character-
istics. Although we ascertained the acetaminophen
cases manually in order to minimize the misclassiﬁca-
tion as described in the Patients and Methods section,
misclassiﬁcation of acetaminophen and nonacetamino-
phen Status-1A cases is still plausible due to the
incomplete information, missing data, and the inability
to conﬁrm the cause of FHF with the submitting cen-
ters. The results of our study cannot necessarily be
applied to candidates awaiting second liver transplants
after primary graft nonfunction or to children, because
these groups were excluded from our study cohort.
Despite these limitations, our study is the ﬁrst to dem-
onstrate the comparability of wait-list mortality risk of
Status-1A and ESLD candidates with high MELD
scores.
MELD score may serve as a reasonable tool in rank-
ing acetaminophen FHF Status-1A candidates on the
transplant waiting list. However, further studies using
the cross-classiﬁcations of acetaminophen FHF Status-
1A and ESLD candidates with MELD score 36 for
wait-list mortality risk stratiﬁcation must be done to
validate MELD score as an evidence-based allocation
tool among these candidates. The MELD score was
not a signiﬁcant predictor of wait-list mortality among
nonacetaminophen FHF Status-1A candidates. Another
approach would be allocation of deceased donor livers
by survival beneﬁt7; however, this may require addi-
tional investigation and further validation.
In conclusion, our study has shown that ESLD can-
didates with MELD > 40 have higher wait-list mortal-
ity rates than Status-1A candidates. In addition, ESLD
candidates with MELD scores 36 to 40 have wait-list
mortality similar to that of Status-1A. Regardless of
their wait-list mortality, the LT recipients with MELD
scores > 20, including those with MELD > 40, have
similar posttransplant survival as Status-1A recipients.
These results imply that an evidence-based modiﬁca-
tion in the current allocation scheme may further
reduce overall wait-list mortality without compromis-
ing posttransplant survival.
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